Implementation and Accuracy of BinaxNOW Rapid Antigen COVID-19 Test in Asymptomatic and Symptomatic Populations in a High-Volume Self-Referred Testing Site
Zishan K. Siddiqui, Mihir Chaudhary, Matthew L. Robinson, Anna B. McCall, Ria Peralta, Rogette Esteve, Charles W. Callahan, Yukari C. Manabe, James D. Campbell, J. Kristie Johnson, Maryam Elhabashy, Melinda Kantsiper, James R. Ficke
Abstract
The BinaxNOW rapid antigen COVID-19 test had a sensitivity of 87% in symptomatic and 71% asymptomatic individuals when performed by health care workers in a high-throughput setting. The performance may expedite isolation decisions or referrals for time-sensitive monoclonal antibody treatment in communities where timely COVID PCR tests are unavailable.
Topics & Concepts
AsymptomaticMedicineConfidence intervalAntigenInternal medicineTest (biology)False Negative ReactionsAsymptomatic carrierDiagnostic testPredictive value of testsImmunologyIsolation (microbiology)Young adultClinical PracticeClinical trialRetrospective cohort studySARS-CoV-2 detection and testingSARS-CoV-2 and COVID-19 ResearchBiosensors and Analytical Detection